Background: Detrimental bidirectional pharmacokinetic interactions have been observed when telaprevir (TVR) and ritonavir (RTV)-boosted human immunodeficiency virus (HIV) protease inhibitors are coadministered in healthy volunteers. Our aim was to evaluate the role of RTV in the bidirectional TVR and atazanavir (ATV) interactions.
Method: An open-label, sequential study was carried out in hepatitis C virus (HCV)/HIV-coinfected patients on a RTV-boosted ATV-based (ATVr) antiretroviral regimen (300/100 mg every 24 hours) and triple therapy for chronic C hepatitis genotype 1 (TVR, 1125 mg every 12 hours, pegylated interferon-alpha and ribavirin). Pharmacokinetic profiles were acquired before and after switching from ATVr to unboosted ATV (200 mg every 12 hours). The plasma levels of both drugs were determined by liquid chromatography coupled with mass spectrometry. Pharmacokinetic parameters were calculated by noncompartmental analysis and compared by geometric mean ratios and their 90% confidence intervals.
Results: Fourteen white HCV/HIV-coinfected males were enrolled in this study. After RTV was withdrawn, the TVR AUC(0-12) (area under the concentration-time curve), maximum concentration (C(max)), and minimum concentration (C(min)) values increased by 19% (7%-30%), 12% (0.9%-29%), and 18% (2%-34%), respectively, without any changes in the TVR terminal half-life. The ATV AUC(0-12), C(max), and C(min) values were 39% (13%-66%), 19% (8%-59%), and 48% (1%-96%) higher, respectively, with a significantly shorter terminal half-life (22.6 hours vs 10.4 hours).
Conclusions: RTV is responsible for the adverse interactions that occur when TVR and ATVr are administered together, possibly by influencing either the absorption phase or first-pass metabolism of TVR. The boost effect of TVR on ATV exposure is higher than on RTV, despite its shorter terminal half-life. The coadministration of TVR and unboosted ATV results in increased exposure of both drugs compared with their coadministration with RTV.
Clinical Trials Registration: ClinicalTrials.gov: NCT01818856. European Medicines Agency EudraCT no. 2012-002515-25.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/cit693 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Public Health.
Alzheimers Dement
December 2024
Rutgers, The State University of New Jersey, Newark, NJ, USA.
Background: Most older adults prefer aging in place; however, patients with dementia and advanced illness often need institutional care, even if only for a brief period of time. In the context of the aging US population and the increasing number of individuals living with dementia, understanding place of care trajectory patterns is important for patient-centered care planning and health policy decisions. The purpose of this study was to characterize place of care trajectories during the last three years of life among Medicare beneficiaries diagnosed with dementia.
View Article and Find Full Text PDFRationale: Prior work has shown a preference among most people with dementia and their families for comfort-focused care near the end-of-life. Nonetheless, intubation and mechanical ventilation are increasing over time without concurrent trends in improved survival, including among those with advanced dementia. A better understanding of prehospital decision-making about intubation for people with dementia will guide efforts to increase goal-concordant care at onset of critical illness.
View Article and Find Full Text PDFFeasibility of teleyoga for people with post COVID-19 condition- a mixed method design.
BMC Complement Med Ther
January 2025
Department of Health Medicine and Caring Sciences, Linkoping University, Linköping, Sweden.
Background: Evidence about rehabilitation of post COVID-19 condition is scarce. Yoga has been found beneficial in other chronic conditions and can be delivered in a digital format at home. The aim of the study was to explore the feasibility of teleyoga in persons with post COVID-19 condition by assessing adherence, safety, limited efficacy and experiences.
View Article and Find Full Text PDFImpact of Sotorasib, a KRAS G12C Inhibitor, on the Pharmacokinetics and Therapeutic Window of Digoxin, a P-Glycoprotein Substrate.
Clin Pharmacol Drug Dev
January 2025
Clinical Pharmacology Modeling and Simulation, Amgen Inc., Thousand Oaks, CA, USA.
Sotorasib is a small-molecule Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C inhibitor indicated for the treatment of KRAS G12C-driven cancers. KRAS G12C is a common mutation in solid tumors, including non-small cell lung cancer. In vitro studies suggested that sotorasib is a weak inhibitor of P-glycoprotein transporter.
View Article and Find Full Text PDFComplementary and Alternative Medicine Use in the Last Year of Life: The COMPASS Cancer Cohort Study.
J Pain Symptom Manage
January 2025
Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore; Programme in Health Services and Systems Research, Duke-NUS Medical School, Singapore.
Context: There has been growing interest in the role of complementary and alternative medicine (CAM) as part of end-of-life care.
Objectives: This study prospectively examined the prevalence, predictors and outcomes of ingestible CAM use among cancer patients in their last year of life in Singapore.
Methods: This study (N=427) utilized data across 12 months (4 time points) prior to patient death.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!